+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

CRISPR Technology Market

  • PDF Icon

    Report

  • 122 Pages
  • October 2024
  • Region: Global
  • BCC Research
  • ID: 6019943
The CRISPR Technology Market was valued at USD 3.8 Billion in 2024, and is expected to reach USD 7.5 Billion by 2029, rising at a CAGR of 14.40%.

This report on CRISPR technology provides market projections for 2029 and analyzes the market for CRISPR technology by application and end user. Applications covered include drug development, agriculture, diagnostics and others. End users include biotechnology and pharmaceutical companies, academics and government research institutes, and contract research organizations.

Report Scope

This report on CRISPR technology provides market projections for 2029 and analyzes the market for CRISPR technology by application and end user. Applications covered include drug development, agriculture, diagnostics and others. End users include biotechnology and pharmaceutical companies, academics and government research institutes, and contract research organizations.

The report includes:

  • 32 data tables and 61 additional tables
  • An analysis of the global market for CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology
  • Analyses of the global market trends, with data from 2021-2022, estimates for 2023, forecast for 2024, and projected CAGRs through 2029
  • Discussion of the market potential for CRISPR technology
  • Estimate of the market size and a revenue forecast for the global CRISPR technology market, and a corresponding market share analysis by application, end user, and region
  • Discussion of the major market dynamics, regulations, industry challenges, and macroeconomic factors that will affect the demand for CRISPR technology market over the next five years
  • A look at the recent breakthrough in CRISPR-Cas9 genome editing technology, and how it has propelled the rapid growth in genetic engineering and advanced pharmacological research
  • A comparative study on CRISPR with TALE and ZFN nuclease as a gene editing tool and discussion on its higher adaptability over other nucleases
  • Review of the patent filings and research publications for innovations in the CRISPR-Cas9 genome editing technology
  • A discussion on ESG challenges and ESG practices of the industry participants
  • A look at the proprietary technologies and strategic alliances of the companies best positioned in the CRISPR market
  • Analysis of the industry structure, competitive landscape, clinical trials, ongoing research activities, and the impact of COVID-19
  • Company profiles of the major players, including Merck KGaA, Thermo Fisher Scientific, Beam Therapeutics, CRISPR Therapeutics and Danaher Corp.

Table of Contents

Chapter 1 Executive Summary
  • Market Outlook
  • Scope of Report
  • Market Summary
Chapter 2 Market Overview
  • Genome Editing
  • CRISPR
  • Introduction
  • Components of CRISPR
  • Mechanism of Action
  • CRISPR Gene Editing Workflow
  • Advantages and Disadvantages of CRISPR Technology
  • Pricing Analysis
  • PESTLE Analysis
  • Porter's Five Forces Analysis
  • Regulatory Landscape, by Type
  • Human
  • Gene Drives
  • Agriculture
  • Animals
  • Regulatory Landscape, by Region
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
Chapter 3 Market Dynamics
  • Market Dynamics Snapshot
  • Market Drivers
  • Rising Incidence of Chronic Diseases
  • Prevalence of Genetic Disorders
  • Government and Private Funding
  • Market Restraints
  • Alternative Technologies
  • Market Opportunities
  • Increase in the Number of Applications
  • Market Challenges
  • Complex and Evolving Regulatory Landscape
  • High Cost of CRISPR-based Therapy
Chapter 4 Emerging Technologies and Developments
  • Emerging Technologies
  • In Vivo Delivery of CRISPR
  • Improved Cas Variants
  • Artificial Intelligence
  • Clinical Trials Analysis
  • Clinical Trials Analysis, by Type of Study
  • Clinical Trials Analysis, by Status
  • Clinical Trials Analysis, by Phase
  • Clinical Trials
  • Patent Analysis
  • Patents, by Year
  • Patents, by Top Applicant
  • Patents, by Top Owner
  • Patents, by Jurisdiction
  • Intellectual Property Disputes and Patent Issues
Chapter 5 Market Segmentation Analysis
  • Segmentation Breakdown
  • Market Breakdown, by Application
  • Drug Development
  • Agriculture
  • Diagnostics
  • Other Applications
  • Market Breakdown, by End User
  • Biotech and Pharmaceutical Companies
  • Academics and Government Research Institutes
  • Contract Research Organizations
  • Geographic Breakdown
  • Market Analysis, by Region
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
Chapter 6 Competitive Intelligence
  • Market Analysis
  • Strategic Analysis
Chapter 7 Sustainability in CRISPR Technology: An ESG Perspective
  • Introduction to ESG
  • Sustainability in CRISPR Technology: An ESG Perspective
  • Key ESG Issues
  • CRISPR Technology ESG Performance Analysis
  • Environmental Performance
  • Social Performance
  • Governance Performance
  • Concluding Remarks
Chapter 8 Appendix
  • Methodology
  • References
  • Abbreviations
  • Company Profiles
  • AGILENT TECHNOLOGIES INC.
  • BEAM THERAPEUTICS
  • CARIBOU BIOSCIENCES INC.
  • CRISPR THERAPEUTICS
  • DANAHER CORP.
  • EDITAS MEDICINE
  • GENSCRIPT
  • INTELLIA THERAPEUTICS INC.
  • LONZA
  • MERCK KGAA
  • THERMO FISHER SCIENTIFIC INC.
List of Tables
Summary Table: Global Market for CRISPR Technology, by Application, Through 2029
Table 1: Comparison of Genome Editing Techniques
Table 2: Comparison of sgRNA Formats
Table 3: Comparison of Cas Enzymes
Table 4: Pricing Analysis of CRISPR Technology Products, by Company
Table 5: Regulatory Rating: Human Gene Editing, by Country/Region
Table 6: Regulatory Rating: Gene Drives, by Country/Region
Table 7: Regulatory Rating: Crops/Food, by Country/Region
Table 8: Regulatory Rating: Animals, by Country/Region
Table 9: Regulatory Landscape in Asia-Pacific Countries
Table 10: Regulatory Landscape in South American Countries
Table 11: Chronic Diseases: Applications of CRISPR-based Therapy
Table 12: Genetic Disease: CRISPR-based Therapy
Table 13: CRISPR Technology: Venture Funding, 2021-2024
Table 14: Clinical Trials in CRISPR Technology, by Type of Study, August 2024
Table 15: Clinical Trials in CRISPR Technology, by Status, August 2024
Table 16: Clinical Trials in CRISPR Technology, by Phase, August 2024
Table 17: Select Clinical Trials, 2024
Table 18: Patents Granted on CRISPR Technology, by Top Applicant, 2020-2023
Table 19: Patents Granted on CRISPR Technology, by Top Owner, 2020-2023
Table 20: Patents Granted on CRISPR Technology, by Jurisdiction, 2020-2023
Table 21: Global Market for CRISPR Technology, by Application, Through 2029
Table 22: CRISPR-Based Genetic Therapy: Pipeline, 2024
Table 23: Global Market for Drug Development in CRISPR Technology, by Region, Through 2029
Table 24: CRISPR-Edited Crops
Table 25: Global Market for Agriculture in CRISPR Technology, by Region, Through 2029
Table 26: CRISPR-based Diagnostics
Table 27: Global Market for Diagnostics in CRISPR Technology, by Region, Through 2029
Table 28: Global Market for Other Applications in CRISPR Technology, by Region, Through 2029
Table 29: Global Market for CRISPR Technology, by End User, Through 2029
Table 30: Biotech and Pharmaceutical Partners of CRISPR Technology Companies
Table 31: Recent Collaborations Among Biotech, Pharma and CRISPR Technology Firms, 2023-2024
Table 32: Global Market for Biotech and Pharma Companies for CRISPR Technology, by Region, Through 2029
Table 33: Global Market for Academics and Government Research Institutes for CRISPR Technology, by Region, Through 2029
Table 34: Global Market for CRO for CRISPR Technology, by Region, Through 2029
Table 35: Global Market for CRISPR Technology, by Region, Through 2029
Table 36: North American Market for CRISPR Technology, by Country, Through 2029
Table 37: European Market for CRISPR Technology, by Country, Through 2029
Table 38: Asia-Pacific Market for CRISPR Technology, by Country, Through 2029
Table 39: Leading Companies in the CRISPR Technology Market
Table 40: Small and Medium-Sized Companies in the CRISPR Technology Market
Table 41: Recent Developments in the CRISPR Technology Market, 2022-2024
Table 42: Bioethical Issues and Risks Associated with CRISPR Technology
Table 43: ESG Rankings for CRISPR Technology Companies, 2024*
Table 44: ESG: Environmental Overview
Table 45: ESG: Social Overview
Table 46: ESG: Governance Overview
Table 47: Information Sources in this Report
Table 48: Abbreviations Used in this Report
Table 49: Agilent Technologies Inc.: Company Snapshot
Table 50: Agilent Technologies Inc.: Financial Performance, FY 2022 and 2023
Table 51: Agilent Technologies Inc.: Product Portfolio
Table 52: Agilent Technologies Inc.: News/Key Developments, 2021
Table 53: Beam Therapeutics: Company Snapshot
Table 54: Beam Therapeutics: Financial Performance, FY 2022 and 2023
Table 55: Beam Therapeutics: Product Portfolio
Table 56: Beam Therapeutics: News/Key Developments, 2021-2023
Table 57: Caribou Biosciences Inc.: Company Snapshot
Table 58: Caribou Biosciences Inc.: Financial Performance, FY 2022 and 2023
Table 59: Caribou Biosciences Inc.: Product Portfolio
Table 60: Caribou Biosciences Inc.: News/Key Developments, 2021-2023
Table 61: CRISPR Therapeutics: Company Snapshot
Table 62: CRISPR Therapeutics: Financial Performance, FY 2022 and 2023
Table 63: CRISPR Therapeutics: Product Portfolio
Table 64: CRISPR Therapeutics: News/Key Developments, 2022-2024
Table 65: Danaher Corp.: Company Snapshot
Table 66: Danaher Corp.: Financial Performance, FY 2022 and 2023
Table 67: Danaher Corp.: Product Portfolio
Table 68: Danaher Corp.: News/Key Developments, 2021-2024
Table 69: Editas Medicine: Company Snapshot
Table 70: Editas Medicine: Financial Performance, FY 2022 and 2023
Table 71: Editas Medicine: Product Portfolio
Table 72: Editas Medicine: News/Key Developments, 2022 and 2023
Table 73: GenScript: Company Snapshot
Table 74: GenScript: Financial Performance, FY 2022 and 2023
Table 75: GenScript: Product Portfolio
Table 76: GenScript: News/Key Developments, 2021
Table 77: Intellia Therapeutics Inc.: Company Snapshot
Table 78: Intellia Therapeutics Inc.: Financial Performance, FY 2022 and 2023
Table 79: Intellia Therapeutics Inc.: Product Portfolio
Table 80: Intellia Therapeutics Inc.: News/Key Developments, 2021-2023
Table 81: Lonza: Company Snapshot
Table 82: Lonza Financial Performance, FY 2022 and 2023
Table 83: Lonza: Product Portfolio
Table 84: Lonza: News/Key Developments, 2022-2024
Table 85: Merck KGaA: Company Snapshot
Table 86: Merck KGaA: Financial Performance, FY 2022 and 2023
Table 87: Merck KGaA: Product Portfolio
Table 88: Merck KGaA: News/Key Developments, 2021
Table 89: Thermo Fisher Scientific Inc.: Company Snapshot
Table 90: Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
Table 91: Thermo Fisher Scientific Inc: Product Portfolio
Table 92: Thermo Fisher Scientific Inc.: News/Key Developments, 2021 and 2022
List of Figures
Summary Figure: Global Market for CRISPR Technology, by Application, 2021-2029
Figure 1: CRISPR: Mechanism of Action
Figure 2: CRISPR Gene Editing: Workflow
Figure 3: Advantages and Disadvantages of CRISPR Technology
Figure 4: PESTLE Analysis - CRISPR Technology
Figure 5: Market Dynamics of CRISPR Technology
Figure 6: Estimated Numbers of All Cancer Cases, Both Sexes, 2022-2050
Figure 7: Global Estimates: People with Diabetes (20 to 79), 2021-2045
Figure 8: Emerging Trends/Technologies in the CRISPR Technology Market
Figure 9: Patents Granted on CRISPR Technology, by Year, 2020-2022
Figure 10: Global Market Shares for CRISPR Technology, by Application, 2023
Figure 11: CRISPR Technology in Drug Development
Figure 12: Uses of CRISPR in Agriculture
Figure 13: Global Market Shares for CRISPR Technology, by End User, 2023
Figure 14: Number of Scientific Publications on CRISPR, by Year, 2020-2023
Figure 15: Global Market Shares for CRISPR Technology, by Region, 2023
Figure 16: North American Market Shares of CRISPR Technology, by Country, 2023
Figure 17: U.S. Market for CRISPR Technology, 2021-2029
Figure 18: Canadian Market for CRISPR Technology, 2021-2029
Figure 19: European Market Shares of CRISPR Technology, by Country, 2023
Figure 20: German Market for CRISPR Technology, 2021-2029
Figure 21: U.K. Market for CRISPR Technology, 2021-2029
Figure 22: French Market for CRISPR Technology, 2021-2029
Figure 23: Rest of the European Market for CRISPR Technology, 2021-2029
Figure 24: Asia-Pacific Market Shares of CRISPR Technology, by Country, 2023
Figure 25: Chinese Market for CRISPR Technology, 2021-2029
Figure 26: Japanese Market for CRISPR Technology, 2021-2029
Figure 27: Indian Market for CRISPR Technology, 2021-2029
Figure 28: Rest of Asia-Pacific Market for CRISPR Technology, 2021-2029
Figure 29: RoW Market for CRISPR Technology, 2021-2029
Figure 30: Pillars of ESG
Figure 31: Advantages of ESG for Companies
Figure 32: Methodology Used in the CRISPR Technology Market
Figure 33: Agilent Technologies Inc.: Revenue Share, by Business Unit, FY 2023
Figure 34: Agilent Technologies Inc.: Revenue Share, by Region, FY 2023
Figure 35: Caribou Biosciences Inc.: Revenue Share, by Business Unit, FY 2023
Figure 36: Caribou Biosciences Inc.: Revenue Share, by Country/Region, FY 2023
Figure 37: Danaher Corp.: Market Share, by Business Unit, FY 2023
Figure 38: Danaher Corp.: Revenue Share, by Country/Region, FY 2023
Figure 39: GenScript: Revenue Share, by Business Unit, FY 2023
Figure 40: GenScript: Revenue Share, by Country/Region, FY 2023
Figure 41: Lonza: Revenue Share, by Business Unit, FY 2023
Figure 42: Lonza: Revenue Share, by Country/Region, FY 2023
Figure 43: Merck KGaA: Revenue Share, by Business Unit, FY 2023
Figure 44: Merck KGaA: Revenue Share, by Region, FY 2023
Figure 45: Thermo Fisher Scientific Inc.: Market Share, by Business Unit, FY 2023
Figure 46: Thermo Fisher Scientific Inc.: Revenue Share, by Region, FY 2023

Companies Mentioned

Some of the major companies in the CRISPR Technology market, which are profiled in this report include:
  • Agilent Technologies Inc.
  • Beam Therapeutics
  • Caribou Biosciences Inc.
  • Crispr Therapeutics
  • Danaher Corp.
  • Editas Medicine
  • Genscript
  • Intellia Therapeutics Inc.
  • Lonza
  • Merck KGaA
  • Thermo Fisher Scientific Inc.

Table Information